Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

A Porcine Model of Intervertebral Disc Injury Recapitulates Human Discogenic Pain Via Notochordal Cell Loss and Pain-Inducing Nucleus Pulposus Cell Emergence

Kaneda G, Wechsler JT, Chavez M, Sheyn J, Cheema K, Shen C, Rigo De Righi D, Wang L, Hsu YC, Avalos P, Xie Y, Tawackoli[...]

Integrating Natural Language Processing With ChatGPT to Improve Quality of Artificial Intelligence Summaries of Prostate Cancer Consultations

Friedrich NA, Das SK, Luu M, Daniels JP, Heard J, Barsegyan A, Freedland SJ, Spiegel B, Kokorowski PK, Gonzalez Hernandez G, Daskivich TJ. Integrating Natural[...]

Clinical Triage of Individuals With Warning Symptoms of Imminent Cardiac Arrest

Reinier K, Chugh H, Kadiyala V, Sargsyan A, Uy-Evanado A, Nakamura K, Heckard E, Mathias M, Grogan T, Elashoff D, Salvucci A, Jui J, Chugh[...]